Search
Close this search box.

Innovative scalable technologies for production of cell therapies

The project aims to produce innovative modular technologies for the production of cell therapies with improved scalability, enhanced co, consistency, and efficacy, and the potential for reduced cost.
Categories
Cell and Gene therapies
Process control
Project status
76% Completed

Industry Need

  • Cell therapies, such as chimeric antigen receptor (CAR)-T cells, are increasingly important for treating cancer and other maladies. 
  • Production of such therapies involves a series of time intensive steps that have been translated from cell biology laboratory-based procedures. 


Solution

The University of Delaware and team aim to develop innovative modular technologies to produce cell therapies with improved scalability, enhanced consistency and efficacy, and the potential for reduced cost


A prototype technology recently was established that integrates scalable, functionalized soft membranes into a flow-based device for enhancing T cell transduction and promoting T cell activation (completed PC3.1-132).  


This work (PC5.2T-108) will build from this successful prototype to address more processing steps and other cell therapies, facilitated by the growth of our academic-industrial partnerships. Specifically, the goals of this project are to: 

  • Generate workflow designs for prototype operation in different processing steps individually and in combination for scalable production with improved sterility, selection, transduction, activation, and expansion of desired T cell phenotypes, and  
  • Translate the device to other cell types (macrophages, natural killer cells, induced pluripotent stem cells) for establishing prototypes for transduction of these difficult-to-transduce primary human cells and of relevance for manufacturing of cell therapies for immunoengineering.


Outcomes and Impacts

Establish workflows for enhancing the transduction of difficult-to-transduce cell types

Establish functionalities and workflows for cost-effective, short-term rapid T-cell processing steps.

Demonstrate devices for longer-term T-cell processing steps including closed-loop phenotype selection, activation, expansion, and transduction

Updates, Related Publications, and Deliverables

  • Login to the NIIMBL member portal for access to project updates, related publications, and deliverables. 

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

University of Delaware

University of Delaware

Participating Organizations

Agilent

Agilent

MilliporeSigma/EMD Serono

MilliporeSigma/EMD Serono

Join Our Mailing List

MailChimp NIIMBL Mailing List Signup
Organization Type
How did you first hear about NIIMBL?